JAZZJazz Pharmaceuticals

About Jazz Pharmaceuticals
Jazz Pharmaceuticals (NASDAQ:JAZZ) is a biopharmaceutical company focused on developing and commercializing innovative medicines to address unmet medical needs in various therapeutic areas, including sleep disorders and oncology. It has a diverse portfolio of marketed products, along with a dynamic pipeline of potential therapies in various stages of development. The company aims to transform the lives of patients by creating and offering options for complex healthcare challenges. Jazz Pharmaceuticals is committed to achieving these objectives through its dedication to innovation, collaborative research, and compassionate patient care.
What is JAZZ known for?
Snapshot
Public US
Ownership
2005
Year founded
3242
Employees
Dublin, Ireland
Head office
1 of 4
US Rank
Unknown
Sector
N/A
Sector rank
Loading Map...
Operations
All Locations
Ireland
Produtos e/ou serviços de Jazz Pharmaceuticals
- Xywav for narcolepsy with cataplexy or excessive daytime sleepiness
- Vyxeos for acute myeloid leukemia
- Defitelio for hepatic veno-occlusive disease
- Zepzelca for small cell lung cancer
- Sunosi for excessive daytime sleepiness due to narcolepsy or obstructive sleep apnea
- Epidiolex for seizures associated with Lennox-Gastaut syndrome or Dravet syndrome
equipe executiva do Jazz Pharmaceuticals
- Mr. Bruce C. CozaddCo-Founder & Chairman
- Ms. Renee D. GalaPresident, CEO & Director
- Mr. Philip L. JohnsonExecutive VP & CFO
- Ms. Patricia CarrSenior VP & Chief Accounting Officer
- Dr. Robert Iannone M.D.Executive VP, Chief Medical Officer and Global Head of Research & Development
- Ms. Samantha PearceExecutive VP & Chief Commercial Officer
- Jack W. SpinksExecutive Director of Investor Relations
- Ms. Neena M. Patil J.D.Executive VP & Chief Legal Officer
- Ms. Heidi MannaExecutive VP & Chief People Officer
- Dr. Jed Black M.D.Senior Vice President of Sleep & CNS Medicine